fimasartan + indapamide placebo

fimasartan + indapamide placebo refers to a specific treatment arm used in clinical trials conducted by Boryung Pharmaceutical, notably the Phase III study NCT05878561. This preparation consists of the active drug fimasartan, a non-peptide angiotensin II receptor antagonist (ARB), administered alongside an inactive placebo designed to mimic indapamide. Fimasartan works by selectively blocking the AT1 receptor subtype, thereby inhibiting the vasoconstrictive and aldosterone-secreting effects of angiotensin II, which leads to reduced systemic vascular resistance and lower blood pressure. In the context of the BR1015 development program, this placebo-controlled monotherapy serves as the comparator to evaluate the incremental efficacy and safety of adding indapamide (a thiazide-like diuretic) to fimasartan in patients with essential hypertension who are not adequately controlled by fimasartan 30 mg alone.

Brand names

Kanarb

Other names

fimasartan monotherapy